Press Releases

AONN+'s ER+ Premenopausal Breast Cancer Journey Pathway Wins PM360 Pharma Choice Award

Cranbury, NJ (February 28, 2024)—The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to share that PM360, a leading trade magazine for marketing decision-makers in the pharmaceutical, biotech, medical device, and diagnostic industries, has named AONN+’s estrogen-receptor-positive (ER+) Premenopausal Breast Cancer Journey Pathway, supported by TerSera Therapeutics, as the Pharma Choice Award – Variety Silver Winner.

The Academy of Oncology Nurse & Patient Navigator’s (AONN+) Precision Medicine Toolkit Named One of the Most Interesting Innovations of 2023 by PM360

Langhorne, PA — PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, included AONN+’s Precision Medicine Toolkit: A Resource Guide for the Navigator in its annual Innovations Issue, which highlights the most interesting advancements in the life sciences, healthcare, and marketing in 13 categories. AONN+’s Precision Medicine Toolkit was included within the Life Sciences category.

The Academy of Oncology Nurse & Patient Navigators (AONN+) Lauds CMS’ Final Rule Paving Way for Payment of Patient Navigation Services

CRANBURY, NJ (Nov. 9, 2023) – Payment for navigation services has long been a legislative priority for the Academy of Oncology Nurse & Patient Navigators (AONN+). Now, with the recent release of the Centers for Medicare & Medicaid Services (CMS) 2024 Medicare Physician Fee Schedule (PFS) Final Rule, this goal is finally being realized, further recognizing and validating the important role patient navigators play in the care continuum.

The Era of the Patient Navigator Is Now

Finally recognized as a vital part of a cancer patient’s full continuum of care, patient navigators are on the cusp of being formally acknowledged for the important role they play in ensuring a patient’s quality of life and care through their challenging and complex ordeals. Cancer continues to be called the “emperor of all maladies” and, according to the World Health Organization, is the leading cause of death worldwide.

The Academy of Oncology Nurse & Patient Navigators (AONN+) Selects Sites to Participate in National Acuity Quality Initiative

CRANBURY, NJ (Oct. 4, 2023) – The Academy of Oncology Nurse & Patient Navigators’ (AONN+) National Navigation Acuity Taskforce is developing a standardized, validated, evidence-based Navigation Acuity Tool for oncology navigation programs. When finalized, the acuity tool is expected to help oncology navigators characterize the intensity of the patient navigation workload, aid in the allocation of resources, and measure the effectiveness of navigation on patient outcomes.

The Academy of Oncology Nurse & Patient Navigators (AONN+) Announces New Leadership Council Members

CRANBURY, NJ—Each year, the AONN+ Leadership Council strives to bring novel ideas and perspectives to the table through the addition of new members.

The Academy of Oncology Nurse & Patient Navigators (AONN+) Calls Upon Healthcare Teams to Integrate Sustainable Patient Navigation Services Into Standard Oncology Care

CRANBURY, NJ (Aug. 11, 2023)—Patient navigation is one of the only evidence-based interventions that effectively addresses disparities in oncology care.

Tigerlily Foundation and the Academy of Oncology Nurse & Patient Navigators (AONN+) Partner on #InclusionPledge to Eliminate Disparities for Black Women Living with Breast Cancer

April 24, 2023 - Tigerlily Foundation (Tigerlily) announced today that the Academy of Oncology Nurse & Patient Navigators (AONN+) has committed to the #InclusionPledge—an unprecedented global, multistakeholder initiative focused on diversity, inclusion, and eliminating disparities for Black women living with breast cancer.

AONN+ Policy and Advocacy Committee Kicks Off 2023 by Supporting Two Cancer Leadership Council Letters

The Academy of Oncology Nurse & Patient Navigators’ (AONN+) Policy and Advocacy Committee kicked off 2023 by supporting two Cancer Leadership Council letters. The first was related to the Notice of Benefit and Payment Parameters (NBPP) for 2024, and the second focused on the Essential Health Benefits (EHB) in the Affordable Care Act.

Conquer™ Named 2023 PM360 Pharma Choice Award Gold Winner for Direct to Consumer/Direct to Professional (DTC/DTP)

For the second time, Conquer magazine, the premier forum for patients with cancer, named the winner for the finest, most impactful creative work as decided by popular vote from the entire industry.